A31 (ALK5 PROTAC, West China Hospital)

A31 (ALK5 PROTAC, West China Hospital): sourced facts only. name: "The lead compound, A31, induced ALK5 degradation in NIH3T3 cells and demonstrated inhibition of ALK5 downstream signaling and fibroblast activation." [1] target: "The lead compound, A31, induced ALK5 degradation in NIH3T3 cells and demonstrated inhibition of ALK5 downstream signaling and fibroblast activation." [1] developer: "West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China." [1] stage: "Furthermore, A31 exhibits favorable pharmacokinetics following intraperitoneal administration, in vivo anti-fibrotic efficacy, and no significant toxicity at efficacious doses." [1] modality: "Design, synthesis, and biological evaluation of ALK5 PROTAC degraders for pulmonary fibrosis." [1]